ArticleClinical and translational allergy2013
Management of hypersensivity pneumonitis.
Article in Clinical and translational allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Longstanding hypersensitivity pneumonitis and its response to roflumilast: A review of its likely immunological effects.Respiratory medicine case reports · 2022Article
- A rapid test for the environmental detection of pigeon antigen.The Science of the total environment · 2021Article
- Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis.Journal of asthma and allergy · 2021Article
- Rituximab therapy in a patient with steroid-refractory bird fancier's lung.BMJ case reports · 2020Article
- Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2020Article
- [EGFR-TKI ADR Management Chinese Expert Consensus].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Dendritic Cell Trafficking and Function in Rare Lung Diseases.American journal of respiratory cell and molecular biology · 2017Review
- Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.ERJ open research · 2017Article
- Aripiprazole-induced hypersensitivity pneumonitis.BMJ case reports · 2017Article
- Chronic hypersensitivity pneumonitis.Journal of asthma and allergy · 2016Review
- Draft Genome Sequence of Saccharopolyspora rectivirgula.Genome announcements · 2014Article
- Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Cancer metastasis reviews · 2013Review
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity pneumonitis (HP) is an interstitial lung disease due to a combined type III and IV reaction with a granulomatous inflammation, caused by cytotoxic delayed hypersensitivity lymphocytes, in a Th1/Th17 milieu, chaperoned by a deficient suppressor function of T regulatory cells. Skewing toward a Th2 phenotype is reported for chronic HP. Phenotypic expression and severity depends on environmental and/or host genetic and immune co-factors. The wide spectrum of causative antigens is continuously up-dated with new sources of airborne organic particles and drug-induced HP. The diagnosis requires a detailed history, measurement of environmental exposure, pulmonary function tests, imaging, detection of serum specific antibodies, broncho-alveolar lavage, antigen-induced lymphocyte proliferation, environmental or laboratory-controlled inhalation challenge and lung biopsy. Complete antigen avoidance is the best therapeutic measure, although very difficult to achieve in some cases. Systemic steroids are of value for subacute and chronic forms of HP, but do not influence long term outcome. Manipulation of the immune response in HP holds future promise.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.